Sep 262013

A Phase 3, Randomized, Double-blind, Placebo Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Ivacaftor in Subjects with Cystic Fibrosis who have the R117H-CFTR Mutation.

Our Belfast site was the highest global recruiter with a recruitment rate of 217% (target: 6; randomised 13).  All patients have rolled over to the VX11-770-112 study.

© 2019 NICRN - Terms & Conditions Supported by the HSC R&D Division, Public Health Agency.